Insider Cluster (2 insiders) ·Filed Jul 2, 2026

FTH

Faeth Therapeutics, Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed3mo ago
Insider cluster: 2 insiders, $75K total
Actionable Insight • Neutral

The insider buying is small but directionally positive as both CEO and CFO are adding shares after a dilutive ATM facility. Monitor for pipeline updates or clinical catalysts that could explain the confidence. The ATM overhang remains a risk, but insider accumulation suggests management sees current valuation as attractive.

DirectionNeutral
Confidencemedium
Horizonweeks
Latest settled — T+60d ⚠ clustered
FTH ▲ +26.75% at T+60d
NEUTRAL call ✓ call won +26.75% · α vs SPY +23.74% · entry $22.92 → $29.05
Next anchor: T+1d due 3mo ago
Entry anchored
Jul 1, 03:59 PM ET
via exchange tick
T+1d
—
call — · α —
—
due 3mo ago
T+5d
+41.97%
call +41.97% · α +41.04%
$32.54
settled 3mo ago
T+20d
+25.74%
call +25.74% · α +26.16%
$28.82
settled 2mo ago
T+60d
+26.75%
call +26.75% · α +23.74%
$29.05
settled 7d ago

Price Chart

Loading chart...

Executive Summary

CEO Anand Parikh and CFO Brian Stephenson made open-market purchases totaling ~$235K over a 10-day window, following the company's June 18 ATM offering of up to $150M. The buying is small relative to FTH's $644M market cap (0.04%) but notable as both top executives are buying after a dilutive facility.

Key Financial Metrics

Direction
buying
Total Value
$235.0K
Insiders
2

Key Facts

  • CEO Anand Parikh bought 2,800 shares at $19.76 on June 22 for ~$55K
  • CFO Brian Stephenson made four purchases totaling 7,721 shares at $22.95-$23.61 for ~$180K between June 26 and July 1
  • Total insider buying ~$235K, representing 0.04% of market cap
  • Company filed an ATM offering (up to $150M) on June 18, 13 days before the cluster window ended
  • Market cap: $644M; analyst consensus 80% bullish (8 Buy/4 Strong Buy, 2 Hold)

Financial Impact

Insider purchases of ~$235K are immaterial relative to $644M market cap

dilutioninsider confidence

Risk Factors

  • Dilution risk from the $150M ATM facility, which could pressure share price
  • Early-stage biotech with no approved products or disclosed revenue
  • Insider buying is too small to signal strong conviction; could be routine portfolio allocation

Market Snapshot

Exchange
Nasdaq
Analyst Consensus
80% bullish (10 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-FTH-1782951020281
5 reports for FTH
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for FTH — sortable, filterable
TypeNow
Sep 15, 2026
17d ago
3
NEUTRAL ★ 2/10
$34.24 $31.55▼ −7.86%▼ −10.42%$28.35 (−17.20%)
Aug 11, 2026
7w ago
144
BEARISH ★ 5/10
$28.57 $33.00▼ −15.51%▼ −15.91%$28.35 (+0.77%)
Aug 4, 2026
8w ago
8-K
NEUTRAL ★ 3/10
$25.50 $30.00▲ +17.65%▲ +17.75%$28.35 (+11.18%)
Jul 28, 2026
9w ago
3
NEUTRAL ★ 5/10
$28.93 $24.59▼ −15.00%▼ −20.53%$28.35 (−2.00%)
Jul 2, 2026
13w ago
Insider Cluster
NEUTRAL ★ 3/10
$22.92 $32.54▲ +41.97%▲ +41.04%$28.35 (+23.69%)
Showing 5 of 5

US Market Status

Market Closed — Opens Mon (38h 39m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Jul 2, 2026